Novartis is building a new radioligand plant in China

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hiya. Today, we explore how traditionally underserved sickle cell patients became early recipients of a futuristic gene-editing therapy, see another generative AI drug discovery deal forged, and more.

The need-to-know this morning

• Roche is paying $2.7 billion for Carmot Therapeutics, a privately held company developing treatments for obesity.
• Eyepoint Pharmaceuticals saw its share price nearly quadruple in pre-market trading after its treatment for macular degeneration met its goals in a Phase 2 study.
• The FDA approved Eli Lilly’s Jaypirca as a treatment for chronic lymphocytic leukemia, widening its availability beyond mantle cell lymphoma.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In